LONGEVERON INC

Discover how Longeveron’s insider buying and selling signals investor confidence amid a 57% stock drop and promising Phase 2a results.

Insider RSU and option grants by Longeveron’s chief scientist signal long‑term confidence in its aging‑therapy pipeline, offering a bullish hint amid volatile shares.

Lehr Paul T’s recent Longeveron share sale signals a gradual insider divestment; investors should weigh this cautious shift against the company’s speculative fundamentals and upcoming clinical milestones.

Insider sales by Longeveron’s top execs signal a strategic shift—watch for funding or partnership moves that could change the stock’s trajectory.

CEO Willard H. boosts Longeveron stake by 147%—buying 200k shares while selling 105k—to signal confidence amid a 152% social‑media surge, but clinical milestones still dictate long‑term value.